神经内分泌肿瘤的分子放射性诊断与治疗。
Molecular radiotheranostics for neuroendocrine tumours.
机构信息
Royal Free London NHS Foundation Trust, London, UK
Royal Marsden Hospital & Institute of Cancer Research, London, UK.
出版信息
Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462.
Abstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
摘要
本文讨论了核医学成像和治疗在神经内分泌肿瘤（NETs）管理中的重要作用。生长抑素受体闪烁显像对患者管理的影响明显高于常规成像。分子放疗是 NETs 患者管理的重要组成部分。NETs 患者进行分子放疗的选择基于其放射性核素成像研究的摄取。成像剂与治疗剂具有相同的摄取机制。因此，成像研究预先选择了那些可能在肿瘤内集中辐射的患者。
相似文献
1
Molecular radiotheranostics for neuroendocrine tumours.
Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462.
2
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Scand J Gastroenterol. 2015 Jun;50(6):740-7. doi: 10.3109/00365521.2015.1033454.
3
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Print 2011 Oct.
4
Radiopharmaceuticals used for diagnosis and therapy of NETs.
Hell J Nucl Med. 2023 May-Aug;26 Suppl:19-20.
5
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Ann Oncol. 2001;12 Suppl 2:S47-50. doi: 10.1093/annonc/12.suppl_2.s47.
6
Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Nucl Med Rev Cent East Eur. 2013;16(2):70-4. doi: 10.5603/NMR.2013.0038.
7
Theranostic in Nuclear Medicine - The paradigm of NET.
Hell J Nucl Med. 2023 May-Aug;26 Suppl:42-43.
8
Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Br J Surg. 2001 Jan;88(1):31-40. doi: 10.1046/j.1365-2168.2001.01644.x.
9
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Acta Oncol. 2007;46(6):723-34. doi: 10.1080/02841860701441848.
10
Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
Neuroendocrinology. 2016;103(5):560-6. doi: 10.1159/000441604. Epub 2015 Nov 5.
引用本文的文献
1
Gene Abnormalities and Modulated Gene Expression Associated with Radionuclide Treatment: Towards Predictive Biomarkers of Response.
Genes (Basel). 2024 May 26;15(6):688. doi: 10.3390/genes15060688.
2
Actinium-225 Targeted Agents: Where Are We Now?
Brachytherapy. 2023 Nov-Dec;22(6):697-708. doi: 10.1016/j.brachy.2023.06.228. Epub 2023 Sep 9.
3
Combination of [Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.
Pharmaceutics. 2022 Jun 16;14(6):1284. doi: 10.3390/pharmaceutics14061284.
4
Evaluation of Dosimetric Parameters for Tumor Therapy with Lu and Y Radionuclides in Gate Monte Carlo Code.
J Biomed Phys Eng. 2021 Jun 1;11(3):263-270. doi: 10.31661/jbpe.v0i0.2101-1256. eCollection 2021 Jun.
5
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.
Cancers (Basel). 2019 Aug 31;11(9):1282. doi: 10.3390/cancers11091282.
本文引用的文献
1
Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.
Nucl Med Commun. 2017 Jul;38(7):593-600. doi: 10.1097/MNM.0000000000000685.
2
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
3
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15.
4
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1770-80. doi: 10.1007/s00259-013-2482-z. Epub 2013 Jul 20.
5
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8. doi: 10.1007/s00259-013-2369-z. Epub 2013 Feb 27.
6
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
7
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
Semin Nucl Med. 2012 May;42(3):190-207. doi: 10.1053/j.semnuclmed.2012.01.002.
8
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
J Clin Oncol. 2012 Apr 1;30(10):1100-6. doi: 10.1200/JCO.2011.37.2151. Epub 2012 Mar 5.
9
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).
Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.
10
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
J Clin Oncol. 2011 Jun 10;29(17):2416-23. doi: 10.1200/JCO.2010.33.7873. Epub 2011 May 9.
Zotero 插件